Microbot Medical Inc.
MBOT Healthcare Medical Instruments & Supplies
In the quarter to June 2026, revenue grew 1,047.6%, EPS grew 20.0% and free cash flow fell 98.7%, each against the same quarter a year earlier.
Follow MBOT
Microbot Medical Inc. (MBOT) EV/Sales
As of 16 October 2026, Microbot Medical Inc. (MBOT) trades at a EV/Sales of −2.9×. Over the past ten years it has ranged from −14.4× (March 2020) to 1,042× (April 2016); the current reading is higher than 1% of that period. That is below the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 160× | (66.38%) |
| Mar 2026 | 475× | 1,272.04% |
| Sep 2015 | 34.6× | 3.76% |
| Jun 2015 | 33.4× | (51.72%) |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DXR Daxor Corporation compare | −14.4× |
| MBOT Microbot Medical Inc. | −2.9× |
| NYXH Nyxoah SA compare | 0.7× |
| POCI Precision Optics Corp. compare | 0.9× |
| HBIO Harvard Bioscience, Inc. compare | 1.1× |
| NEPH Nephros Inc. compare | 1.7× |
| MLSS Milestone Scientific, Inc. compare | 3.1× |
| STXS Stereotaxis Inc. compare | 3.1× |
| ZTEKF Zentek Ltd. compare | 288× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)